Lurbinectedin (PM01183) with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC).

被引：0

作者：

Forster, Martin

Calvo, Emiliano

Olmedo Garcia, Maria Eugenia

Pilar Lopez Criado, M.

Moreno, Victor

Soto-Matos, Arturo

Holgado, Esther

Brown, Nicholas F.

Flynn, Michael

Boni, Valentina

Guerra Alia, Eva

Szyldergemajn, Sergio A.

机构：

[1] UCL, London, England

[2] START Madrid, Ctr Integral Oncol Clara Campal, Madrid, Spain

[3] Ramon & Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain

[4] MD Anderson Canc Ctr Madrid, Madrid, Spain

[5] Fdn Jimenez Diaz, E-28040 Madrid, Spain

[6] PharmaMar SAU, Madrid, Spain

[7] Hosp Madrid, Norte Sanchinarro, Spain

[8] Hosp Univ Ramon & Cajal, Madrid, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7509

引用

页数：1

共 50 条

[31] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
Venepalli, N. K.
Hutchison, A. S.
Carbone, D. P.
Johnson, D. H.
Keedy, V. L.
Pao, W.
Sandler, A.
Horn, L.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[32] Considerations for second-line therapy of non-small cell lung cancer
Stinchcombe, Thomas E.
Socinski, Mark A.
ONCOLOGIST, 2008, 13 : 28 - 36
[33] Second-line therapy for advanced non-small-cell lung cancer
Hann C.L.
Brahmer J.R.
Current Oncology Reports, 2006, 8 (4) : 243 - 247
[34] SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
Cullen, M.
LUNG CANCER, 2009, 64 : S13 - S13
[35] Second-line chemotherapy with cyclophosphamide, doxorubicin and vincristine (CAV) in patients with small cell lung cancer (SCLC) initially treated with platinum and etoposide.
Moreau, S
Labrune, S
Gozy, M
Giraud, V
Le Guillou, F
Blivet, S
Chinet, T
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
[36] Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice
Toublanc, Anne-Claire
Guecamburu, Marina
Veillon, Remi
Rosellini, Pietro
Girodet, Pierre-Olivier
Zysman, Maeva
THORACIC CANCER, 2022, 13 (15) : 2248 - 2252
[37] Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).
Jotte, R.
Von Pawel, J.
Spigel, D. R.
Socinski, M. A.
O'Brien, M.
Paschold, E. H.
Mezger, J.
Steins, M.
Bosquee, L.
Bubis, J. A.
Nackaerts, K.
Perez, J. M. Trigo
Clingan, P. R.
Schuette, W.
Lorigan, P.
Reck, M.
Domine, M.
Shepherd, F. A.
McNally, R.
Renschler, M. F.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[38] Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders
Subbiah, V.
Paz-Ares, L.
Besse, B.
Moreno, V.
Peters, S.
Sala, M. A.
Lopez-Vilarino, J. A.
Fernandez, C.
Kahatt, C.
Zeaiter, A.
Zaman, K.
Delord, J. -P.
Martinez, M.
Anton, A.
Awada, A.
Kristeleit, R.
Olmedo, M. E.
Rubio, M. J.
Sarantopoulos, J.
D'Arcangelo, M.
Santoro, A.
Trigo, Jose M.
Sands, J.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S18 - S19
[39] Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Subbiah, Vivek
Paz-Ares, Luis
Besse, Benjamin
Moreno, Victor
Peters, Solange
Angeles Sala, Maria
Antonio Lopez-Vilarino, Jose
Fernandez, Cristian
Kahatt, Carmen
Alfaro, Vicente
Siguero, Mariano
Zeaiter, Ali
Zaman, Khalil
Lopez, Rafael
Ponce, Santiago
Boni, Valentina
Arrondeau, Jennifer
Delord, Jean-Pierre
Martinez, Maite
Wannesson, Luciano
Anton, Antonio
Valdivia, Javier
Awada, Ahmad
Kristeleit, Rebecca
Eugenia Olmedo, Maria
Jesus Rubio, Maria
Sarantopoulos, John
Chawla, Sant P.
Mosquera-Martinez, Joaquin
D'Arcangelo, Manolo
Santoro, Armando
Villalobos, Victor M.
Sands, Jacob
Trigo, Jose
LUNG CANCER, 2020, 150 : 90 - 96
[40] The role of topotecan in treating small cell lung cancer: second-line treatment
von Pawel, J
LUNG CANCER, 2003, 41 : S3 - S8

← 1 2 3 4 5 →